m6A Regulator and Potential Drug Response

General Information of the m6A Regulator (ID: REG00017)
Regulator Name Methyltransferase-like 16 (METTL16)
Synonyms
Methyltransferase 10 domain-containing protein; RNA N6-adenosine-methyltransferase METTL16; N6-adenosine-methyltransferase METTL16; U6 small nuclear RNA (adenine-(43)-N(6))-methyltransferase; METT10D
    Click to Show/Hide
Gene Name METTL16
Regulator Type WRITER ERASER READER
Regulator Link Click to View Full Information of This Regulator
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
Cellular tumor antigen p53 (TP53)
Contusugene ladenovec [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for Contusugene ladenovec. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Contusugene ladenovec through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [2]
QPI-1002 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for QPI-1002. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of QPI-1002 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [3]
Thymoquinone [Phase 2/3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [4]
Ad-p53 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for Ad-p53. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Ad-p53 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [5]
ALT-801 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for ALT-801. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of ALT-801 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [6]
APG-115 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for APG-115. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of APG-115 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [7]
APR-246 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for APR-246. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of APR-246 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [8]
Cenersen [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for Cenersen. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Cenersen through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [9]
INGN-225 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for INGN-225. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of INGN-225 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [10]
ISA-P53-01 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for ISA-P53-01. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of ISA-P53-01 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [11]
Kevetrin [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for Kevetrin. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Kevetrin through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [12]
OPI-1002 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for OPI-1002. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of OPI-1002 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [13]
SGT-53 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for SGT-53. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of SGT-53 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [10]
CGM097 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for CGM097. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of CGM097 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [10]
COTI-2 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for COTI-2. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of COTI-2 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [14]
Dendritic cell vaccine [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for Dendritic cell vaccine. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Dendritic cell vaccine through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [15]
HDM201 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for HDM201. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of HDM201 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [16]
ONYX-015 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for ONYX-015. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of ONYX-015 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [17]
SAR-405838 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for SAR-405838. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of SAR-405838 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [2]
1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [18]
AHL [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for AHL. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of AHL through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [19]
NU-8231 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for NU-8231. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of NU-8231 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [20]
NUTLIN-3 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for NUTLIN-3. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of NUTLIN-3 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [21]
INGN-234 [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for INGN-234. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of INGN-234 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [22]
Pifithrin-alpha [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for Pifithrin-alpha. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Pifithrin-alpha through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [23]
TAR-1 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for TAR-1. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of TAR-1 through regulating the expression of Cellular tumor antigen p53 (TP53). [1], [24]
Extracellular sulfatase Sulf-2 (SULF2)
Disufenton [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular sulfatase Sulf-2 (SULF2) is a therapeutic target for Disufenton. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Disufenton through regulating the expression of Extracellular sulfatase Sulf-2 (SULF2). [25], [26]
G1/S-specific cyclin-D1 (CCND1)
ABT-263 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for ABT-263. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of ABT-263 through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [27], [28]
Briciclib [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for Briciclib. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Briciclib through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [10], [27]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [27], [29]
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [27], [29]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [27], [30]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [27], [29]
7-hydroxycoumarin [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 7-hydroxycoumarin. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of 7-hydroxycoumarin through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [27], [31]
Ryanodine receptor 1 (RYR1)
(O10eq)-Benzyloxycarbonyl-beta-alanylryanodine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ryanodine receptor 1 (RYR1) is a therapeutic target for (O10eq)-Benzyloxycarbonyl-beta-alanylryanodine. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of (O10eq)-Benzyloxycarbonyl-beta-alanylryanodine through regulating the expression of Ryanodine receptor 1 (RYR1). [32], [33]
(O10eq)-beta-alanyl-anhydro-ryanodine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ryanodine receptor 1 (RYR1) is a therapeutic target for (O10eq)-beta-alanyl-anhydro-ryanodine. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of (O10eq)-beta-alanyl-anhydro-ryanodine through regulating the expression of Ryanodine receptor 1 (RYR1). [32], [33]
(O10eq)-beta-alanylryanodine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ryanodine receptor 1 (RYR1) is a therapeutic target for (O10eq)-beta-alanylryanodine. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of (O10eq)-beta-alanylryanodine through regulating the expression of Ryanodine receptor 1 (RYR1). [32], [33]
(O10eq)-beta-guanidinopropionylryanodine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ryanodine receptor 1 (RYR1) is a therapeutic target for (O10eq)-beta-guanidinopropionylryanodine. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of (O10eq)-beta-guanidinopropionylryanodine through regulating the expression of Ryanodine receptor 1 (RYR1). [32], [33]
(O10eq)-guanidino acetylryanodine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ryanodine receptor 1 (RYR1) is a therapeutic target for (O10eq)-guanidino acetylryanodine. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of (O10eq)-guanidino acetylryanodine through regulating the expression of Ryanodine receptor 1 (RYR1). [32], [34]
ANHYDRORYANIDINE [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ryanodine receptor 1 (RYR1) is a therapeutic target for ANHYDRORYANIDINE. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of ANHYDRORYANIDINE through regulating the expression of Ryanodine receptor 1 (RYR1). [32], [33]
Benzyloxycarbonyl-glycylryanodine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ryanodine receptor 1 (RYR1) is a therapeutic target for Benzyloxycarbonyl-glycylryanodine. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Benzyloxycarbonyl-glycylryanodine through regulating the expression of Ryanodine receptor 1 (RYR1). [32], [33]
Di-Benzyloxycarbonyl-guanidino acetylryanodine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ryanodine receptor 1 (RYR1) is a therapeutic target for Di-Benzyloxycarbonyl-guanidino acetylryanodine. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Di-Benzyloxycarbonyl-guanidino acetylryanodine through regulating the expression of Ryanodine receptor 1 (RYR1). [32], [33]
GLYCYLRYANODINE [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ryanodine receptor 1 (RYR1) is a therapeutic target for GLYCYLRYANODINE. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of GLYCYLRYANODINE through regulating the expression of Ryanodine receptor 1 (RYR1). [32], [33]
N-methyl ryanodine-succinamidate [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ryanodine receptor 1 (RYR1) is a therapeutic target for N-methyl ryanodine-succinamidate. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of N-methyl ryanodine-succinamidate through regulating the expression of Ryanodine receptor 1 (RYR1). [32], [33]
Ruthenium red [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ryanodine receptor 1 (RYR1) is a therapeutic target for Ruthenium red. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Ruthenium red through regulating the expression of Ryanodine receptor 1 (RYR1). [32], [33]
Ryanodine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ryanodine receptor 1 (RYR1) is a therapeutic target for Ryanodine. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Ryanodine through regulating the expression of Ryanodine receptor 1 (RYR1). [32], [35]
ARM036 [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ryanodine receptor 1 (RYR1) is a therapeutic target for ARM036. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of ARM036 through regulating the expression of Ryanodine receptor 1 (RYR1). [32], [36]
CDP-1050 [Discontinued in Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ryanodine receptor 1 (RYR1) is a therapeutic target for CDP-1050. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of CDP-1050 through regulating the expression of Ryanodine receptor 1 (RYR1). [32], [34]
S-adenosylmethionine synthase 2 (MAT2A)
AG-270 [Phase 1]
In total 2 mechanisms lead to this potential drug response
 Drug Info 
Response Summary S-adenosylmethionine synthase 2 (MAT2A) is a therapeutic target for AG-270. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of AG-270 through regulating the expression of S-adenosylmethionine synthase 2 (MAT2A). [32], [37]
S-adenosylmethionine synthase 2 (MAT2A) is a therapeutic target for AG-270. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of AG-270 through regulating the expression of S-adenosylmethionine synthase 2 (MAT2A). [32], [38]
Methionine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary S-adenosylmethionine synthase 2 (MAT2A) is a therapeutic target for Methionine. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Methionine through regulating the expression of S-adenosylmethionine synthase 2 (MAT2A). [32], [39]
References
Ref 1 Gene Signatures and Prognostic Values of m6A Regulators in Hepatocellular Carcinoma. Front Genet. 2020 Oct 2;11:540186. doi: 10.3389/fgene.2020.540186. eCollection 2020.
Ref 2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 3 Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate. Bull Exp Biol Med. 2019 Nov;168(1):92-94. doi: 10.1007/s10517-019-04655-1. Epub 2019 Nov 25.
Ref 4 A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61.
Ref 5 Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr;20(4):222-8. doi: 10.1038/cgt.2013.9. Epub 2013 Mar 8.
Ref 6 INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91. doi: 10.1517/14712598.2010.484801.
Ref 7 Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75. doi: 10.1158/1078-0432.CCR-11-1817. Epub 2011 Oct 12.
Ref 8 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.
Ref 9 STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase. J Biol Chem. 2002 May 3;277(18):15813-8. doi: 10.1074/jbc.M201075200. Epub 2002 Feb 26.
Ref 10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 11 Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003 Mar;10(3):224-38. doi: 10.1038/sj.cgt.7700562.
Ref 12 Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. doi: 10.1016/j.drudis.2020.04.023. Epub 2020 May 7.
Ref 13 Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15;118(2):418-27. doi: 10.1002/cncr.26292. Epub 2011 Jun 29.
Ref 14 WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
Ref 15 National Cancer Institute Drug Dictionary (drug id 761551).
Ref 16 Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004 Dec;6(6):611-23. doi: 10.1016/j.ccr.2004.11.012.
Ref 17 SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014 Oct 15;74(20):5855-65. doi: 10.1158/0008-5472.CAN-14-0799. Epub 2014 Aug 21.
Ref 18 Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem. 2006 Oct 19;49(21):6209-21. doi: 10.1021/jm0601194.
Ref 19 2011 Pipeline of Quark Pharm.
Ref 20 Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. J Med Chem. 2009 Nov 26;52(22):7044-53. doi: 10.1021/jm900681h.
Ref 21 An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines. Mol Cancer Ther. 2005 Sep;4(9):1369-77. doi: 10.1158/1535-7163.MCT-04-0341.
Ref 22 Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004 Jul;53(7):633-41. doi: 10.1007/s00262-003-0493-5. Epub 2004 Feb 25.
Ref 23 Regulation of host gene expression by HIV-1 TAR microRNAs. Retrovirology. 2013; 10: 86.
Ref 24 Prevent Oral Cancer With Mouthwash. Introgen Therapeutics.
Ref 25 PM2.5 induces pulmonary microvascular injury in COPD via METTL16-mediated m6A modification. Environ Pollut. 2022 Jun 15;303:119115. doi: 10.1016/j.envpol.2022.119115. Epub 2022 Mar 5.
Ref 26 [KRP-297, MCC-555]. Nihon Rinsho. 2001 Nov;59(11):2200-6.
Ref 27 METTL16 promotes cell proliferation by up-regulating cyclin D1 expression in gastric cancer. J Cell Mol Med. 2021 Jul;25(14):6602-6617. doi: 10.1111/jcmm.16664. Epub 2021 Jun 2.
Ref 28 New selective nonsteroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5-(alpha-azolylbenzyl)-1H-indoles. Bioorg Med Chem Lett. 1999 Feb 8;9(3):333-6. doi: 10.1016/s0960-894x(98)00737-9.
Ref 29 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. doi: 10.1021/jm0580297.
Ref 30 Clinical pipeline report, company report or official report of Onconova.
Ref 31 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. doi: 10.1021/jm0605740.
Ref 32 Human METTL16 is a N(6)-methyladenosine (m(6)A) methyltransferase that targets pre-mRNAs and various non-coding RNAs. EMBO Rep. 2017 Nov;18(11):2004-2014. doi: 10.15252/embr.201744940. Epub 2017 Oct 19.
Ref 33 Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23. doi: 10.1021/jm00062a003.
Ref 34 The Ryanodine Receptor Stabilizer S44121 / Arm036 Improves Peripheral and Respiratory Muscle Function in a Mouse Model of Heart Failure. Circulation. 2014; 130: A13726.
Ref 35 Role of ryanodine receptor channels in Ca2+ oscillations of porcine tracheal smooth muscle. Am J Physiol. 1997 Apr;272(4 Pt 1):L659-64. doi: 10.1152/ajplung.1997.272.4.L659.
Ref 36 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. doi: 10.1042/BJ20070797.
Ref 37 Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol. 2006 Jul;2(7):369-74. doi: 10.1038/nchembio800. Epub 2006 Jun 11.
Ref 38 Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion. J Med Chem. 2021 Apr 22;64(8):4430-4449. doi: 10.1021/acs.jmedchem.0c01895. Epub 2021 Apr 8.
Ref 39 Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells. Gastroenterology. 2007 Jul;133(1):207-18. doi: 10.1053/j.gastro.2007.03.114. Epub 2007 Apr 11.